Insurance Denied Lupus Treatment? How to Appeal Benlysta Denials and Hydroxychloroquine Appeals

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting approximately 1.5 million Americans, with women of color disproportionately affected. Lupus can damage virtually every organ system in the body, requiring treatments ranging from antimalarials and immunosuppressants to biologics like Benlysta (belimumab) and Saphnelo (anifrolumab). Insurance denials for these treatments can accelerate organ damage and increase mortality risk.

If your lupus treatment was denied, here is what you need to know to appeal effectively.

Common Lupus Treatment Denial Types

Benlysta (belimumab) denied as not medically necessary. Despite FDA approval for active SLE since 2011 (and lupus nephritis since 2020), insurers frequently deny Benlysta because patients are being managed on hydroxychloroquine and the insurer argues additional therapy isn't needed. The ACR and EULAR guidelines both support adding Benlysta in patients with inadequately controlled disease.

Hydroxychloroquine (Plaquenil) quantity or Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization issues. During the COVID-19 pandemic, hydroxychloroquine experienced severe shortages. Patients with lupus — for whom HCQ is standard of care, not experimental — were denied refills or had their prescriptions delayed. Similar shortage-related issues have recurred and remain an appeal category.

Saphnelo (anifrolumab) denied as experimental. FDA approved for SLE in 2021, Saphnelo is a type I interferon receptor antagonist. Some insurers still classify it as experimental or require prior anti-dsDNA antibody testing and steroid dependence documentation that was not specified in the FDA approval.

Organ-specific interventions denied. Lupus nephritis may require mycophenolate mofetil (MMF), cyclophosphamide, voclosporin (Lupkynis), or obinutuzumab (Gazyva) — all associated with specific coverage battles. Neuropsychiatric lupus may require treatments not typically covered under a rheumatology benefit.

Prior authorization for standard immunosuppressants. Even azathioprine, MMF, or steroids may require prior authorization for lupus-specific indications, creating delays in treatment initiation.

Common denial codes: CO-50 (not medically necessary), CO-96 (non-covered service), B15 (authorization not obtained), CO-57 (prior coverage not established).

ACR and EULAR Guidelines

The American College of Rheumatology (ACR) SLE Management Recommendations (2023) provide comprehensive guidance on treatment of SLE by manifestation and severity. Key points:

• Hydroxychloroquine is recommended for all patients with SLE unless contraindicated — it is foundational therapy, not optional
• Belimumab (Benlysta) is recommended as an add-on therapy for patients with persistently active SLE despite standard of care
• Voclosporin (Lupkynis) and belimumab are both recommended for lupus nephritis

The European League Against Rheumatism (EULAR) 2023 SLE Recommendations similarly endorse belimumab as part of the treatment algorithm for moderate-to-severe SLE and active lupus nephritis.

For lupus nephritis specifically, the ACR recommends voclosporin (Lupkynis, FDA-approved 2021) or obinutuzumab (Gazyva) as additional treatment options in class III/IV lupus nephritis — all supported by randomized clinical trial data.

Documenting SLE for an Appeal

The following disease activity measures are standard in lupus management and should appear in your medical records:

• SLEDAI-2K (SLE Disease Activity Index) — score above 6 generally indicates active disease
• BILAG (British Isles Lupus Assessment Group) score
• Physician Global Assessment (PGA) score
• Anti-dsDNA antibody titers and complement levels (C3, C4) — serologically active disease strengthens the case for add-on therapy
• Organ-specific findings (urinalysis, GFR, 24-hour urine protein for nephritis; CBC for cytopenias; echocardiogram for pericarditis)

ICD-10 codes:

• M32.9 — Systemic lupus erythematosus, unspecified
• M32.10–M32.19 — SLE with organ or system involvement (renal, pulmonary, neurological, etc.)
• M32.11 — Endocarditis in SLE (Libman-Sacks)
• M32.14 — Glomerular disease in SLE

Step-by-Step Appeal Strategy

Step 1: Gather disease activity documentation. Your rheumatologist's notes should clearly document SLEDAI-2K scores, serological activity, and organ involvement. If disease activity has been inadequately controlled on current therapy, this should be explicit and longitudinal — not just one visit.

Step 2: Document failed or inadequate prior therapies. If the insurer requires failure of hydroxychloroquine before approving Benlysta, document:

• How long HCQ has been used (it takes 3–6 months to reach full effect)
• That HCQ is already being used and disease remains active
• Which other immunosuppressants have been tried (azathioprine, MMF) and outcomes

Step 3: Challenge "experimental" designations with FDA approval history. Benlysta received FDA approval in 2011 for IV and 2017 for subcutaneous administration. Saphnelo received approval in 2021. Include FDA approval letters in your appeal packet.

Step 4: For hydroxychloroquine shortage appeals. If a pharmacy can't fill the prescription due to shortage, document this with the pharmacy's shortage notice. Some state insurance commissioners have issued guidance requiring alternative coverage or expedited prior authorization during shortages.

Step 5: Request an expedited review for active organ-threatening disease. Lupus nephritis with declining GFR, neuropsychiatric lupus, or severe cytopenias may constitute urgent clinical situations warranting expedited appeal (72-hour resolution).

Supporting Evidence to Gather

• Rheumatologist notes with SLEDAI-2K and laboratory data
• Anti-dsDNA, C3, C4 results over time
• Urinalysis, GFR, and 24-hour urine protein (for nephritis)
• Prior medication history with outcomes
• ACR 2023 SLE management recommendations
• EULAR 2023 recommendations
• FDA approval summaries for belimumab, voclosporin, anifrolumab
• Biopsy results if lupus nephritis is present

Fight Back With ClaimBack

Lupus is unpredictable and dangerous when undertreated. ClaimBack helps you build a complete, guideline-backed appeal so your treatment isn't delayed by paperwork.

Start your lupus treatment appeal today

Related Reading

• What Is Medical Necessity?
• How to Write an Insurance Appeal Letter
• Internal vs. External Insurance Appeal: Which Should You File?